Last reviewed 2026-08-25
One compound here is genuinely FDA-approved: PT-141, as Vyleesi, for acquired hypoactive sexual desire disorder in premenopausal women. It works on desire through the central nervous system, which makes it fundamentally different from sildenafil or tadalafil, which act on blood flow. Its approval is narrower than the way it is marketed, and nausea is common enough to matter.
This goal draws real search traffic and had no page behind it, which is worth stating plainly: 143 impressions over the last year and not a single click, because there was nothing to click.
PT-141 is unusual among the compounds on this site in having an actual FDA approval for something close to the reason people seek it out. But that approval is for a specific diagnosis in a specific population, and it is prescribed well beyond that.
It is also worth understanding the mechanism difference. The familiar ED drugs work on blood flow and do nothing for desire. PT-141 acts centrally on melanocortin receptors and targets desire itself, which is a different problem with different candidates.
Every entry carries the level of human evidence for this use — not the compound’s approval status for something else.
| Peptide | Evidence for this goal | FDA status | Typical cost/mo |
|---|---|---|---|
| PT-141 (Bremelanotide) | FDA-approved for this use | FDA-approved | $150–$400 |
| Gonadorelin | Limited human data | Compounded | $80–$200 |
Melanocortin receptor agonist acting centrally on sexual desire rather than on blood flow.
The catch: Approved specifically for acquired hypoactive sexual desire disorder in premenopausal women. Nausea is the most common adverse effect and can be significant. It can also raise blood pressure transiently.
GnRH analogue used to stimulate the body's own LH and FSH production.
The catch: Used in fertility and hormone contexts and often alongside testosterone therapy to maintain testicular function. That is a hormonal use rather than a direct effect on libido.
PT-141 (bremelanotide), FDA-approved as Vyleesi for acquired, generalised hypoactive sexual desire disorder in premenopausal women.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.
PT-141 (Bremelanotide) requires a prescription and medical supervision. Each service below states that a licensed provider reviews your intake and prescribes through a US compounding pharmacy where appropriate. Those are the companies’ own descriptions of how they operate, not findings of ours. Compounded medications are not FDA-approved, and a consultation does not guarantee a prescription.
Some telehealth links below are affiliate links. If you buy through them, we may earn a commission at no extra cost to you. Commission never affects which products or clinics we list, how they are ordered, or what we say about them — see our editorial policy.
Says a board-certified physician reviews each intake and prescribes through a licensed 503A compounding pharmacy where appropriate, and lists a LegitScript certification. Compounded medications are not FDA-approved.
We are not a clinic and do not prescribe. Listing a service here is not a clinical endorsement of it, and you should confirm licensure and pharmacy sourcing yourself before treatment.
Its FDA approval covers premenopausal women with hypoactive sexual desire disorder. It has been studied in men and is prescribed off-label for them, but the approval and the strongest evidence base are in women.
Sildenafil and tadalafil work on blood flow and address the mechanics of erection. PT-141 acts on melanocortin receptors in the central nervous system and targets desire. They address different problems, and one does not substitute for the other.
Nausea is the most common and can be pronounced. Flushing, headache and injection site reactions also occur, and it can cause a transient rise in blood pressure, which matters for anyone with cardiovascular disease.
Our directory lists clinics whose own websites show they offer peptide therapy. We verify what each one actually provides rather than taking a listing at face value.
Browse the provider directory